iPS Academia Japan, Inc.

Sharing the fruits of iPS cell research
for the good of all humanity

Japanese

What's New

News room


Other 2017/04/19

Summaries of 3 newly published patent applications are added to “Patent Portfolio”

We released the summaries of 3 newly published patent applications from our “Patent Portfolio” as follows.
AJ135 Motor neuron disease examination method and therapeutic agent screening method
AJ137 Method for testing for autosomal dominant polycystic kidney disease and method for screening agent for treatment of the disease
AJ138 A method for producing pancreatic buds
Please find the details from each links above.

*We are not disclosing any summaries of unpublished patent applications. After their publication, we announce on “What’s New”, and release on “Patent Portfolio.”

Other 2017/04/07

Updated the “Patent Information”

New patent information relates to iPS cell technologies for the month of February 2017 has been updated.
Please see Patent Information for more details.
We have updated the page once a month.

License-Out 2017/03/27

License Agreement Has Been Entered with GAIA BioMedicine Inc.

We executed a non-exclusive license agreement for internal research with GAIA BioMedicine Inc. which is a start-up company originated from researches in Kyushu University, on the patents related to iPS cells technology which we have been granted a sublicensing right from Kyoto University.

GAIA BioMedicine Inc.

Other 2017/03/24

Updated the “Patent Information”

New patent information relates to iPS cell technologies for the month of January 2017 has been updated.
Please see Patent Information for more details.
We have updated the page once a month.

License-Out 2017/02/03

License Agreement for Research Use Field Has Been Entered with NeuCyte, Inc.

We executed a non-exclusive license agreement with NeuCyte, Inc., a biopharmaceutical company with a focus on neurological diseases, on the patents related to iPS cells technology which we have been granted a sublicensing right from Kyoto University.

NeuCyte provides iPS cell derived neural cells and related services for research use related to CNS drug discovery and pre-clinical drug neurotoxicity and safety assessment.

License-Out 2017/02/02

License Agreement has been entered with ACEL, Inc.

We executed a non-exclusive license agreement with ACEL, Inc. which provides services related to iPS cells and iPS cell derived cells for research use, on the patents about iPS cell technology which we have been granted a sublicensing right from Kyoto University.

ACEL, Inc.

Other 2016/12/19

Our Office Closed Dec. 29 – Jan 3

Our office will be closed for winter holidays from Thursday 29th December 2016 to Tuesday 3rd January 2017.
Please understand that our earliest replay to any inquiries received during the above period will be made on or after Wednesday 4th January 2017.

We apologize for your inconvenience this may cause you during this period.

License-Out 2016/12/14

License Agreement with BlueRock Therapeutics

We executed a non-exclusive license agreement with BlueRock Therapeutics (regenerative medicine company launched by Bayer and Versant Ventures) to grant iPS cell related patents as a platform technology of which we have sublicensing rights from Kyoto University.

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing

License-Out 2016/12/09

License Agreement Has Been Entered with Censo Biotechnologies Ltd.

We executed a non-exclusive license agreement with Censo Biotechnologies Ltd. which provides iPS cells, iPS cell derived cells and related services for research use, on the patents related to iPS cells technology which we have been granted a sublicensing right from Kyoto University.

Censo Biotechnologies Ltd.

License-Out 2016/12/05

License Agreement in Regard to a Patented Invention by the Technion-Israel Institute of Technology, exclusively held by Accellta Ltd., Has Been Entered with iPS PORTAL

We executed a non-exclusive license agreement with iPS PORTAL, Inc. on a patented invention by the Technion-Israel Institute of Technology entitled “Methods of preparing feeder cells-free, xeno-free human embryonic stem cells and stem cell cultures prepared using same” (Our Ref. No. AJ089 / Patent No. JP4613069), which has been exclusively held by Accellta Ltd., and of which we have been granted a non-exclusive license with sublicense right in Japan.

We are sure that the patent will contribute to many company’s business since the patent is highly important for using iPS cells under xeno-free and feeder cells-free conditions. Please feel free to contact us if you are interested in the patent for your iPS cell business in Japan.

1 / 812345...Last »